{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:26:34Z","timestamp":1786112794024,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Phosphoglycerate mutase 1 (PGAM1) is an important glycolytic enzyme that plays a significant role in cancer metabolism. It catalyzes the conversion of 3-phosphoglycerate (3-PG) to 2-phosphoglycerate (2-PG), facilitating energy release during glycolysis. PGAM1 is often upregulated in various cancers, including breast, lung, and prostate cancers, contributing to tumor growth and progression by coordinating glycolysis and anabolic processes which makes it an appealing target for drug development. In this study, we screened drugs, food, and natural compound libraries against PGAM1 by using structure based virtual screening approach. A total of 100 compounds from each library were screened and then docked to find the best plausible modes of the hits. Based on the binding affinities, 5 compounds from each library were selected for molecular interactions analysis. After analyzing the interactions, the top compound from each library was subjected to 200 ns simulation to check the effect of hits on the protein. The simulation results revealed that the hits made stable interactions with the protein during simulation and no confirmational changes were observed in the structure of protein. All these findings suggest that the selected compounds can serve as lead compounds in inhibiting the biological activity of PGAM1, but it requires further experimental investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048660","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:01:38Z","timestamp":1778745698000},"page":"e48660","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Utilizing drugs, food, and natural product libraries: A computational approach to targeting PGAM1 in clinical cancer therapy"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2565-6573","authenticated-orcid":false,"given":"Abdullah R.","family":"Alanzi","sequence":"first","affiliation":[{"name":"Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hattan A.","family":"Alharbi","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ccr.2012.09.020","article-title":"Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.","volume":"22","author":"Hitosugi","year":"2012","journal-title":"Cancer Cell"},{"key":"R2-20260805","doi-asserted-by":"crossref","first-page":"114798","DOI":"10.1016\/j.ejmech.2022.114798","article-title":"Targeting PGAM1 in cancer: an emerging therapeutic opportunity.","volume":"244","author":"Yang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"R3-20260805","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.3892\/or.2016.5046","article-title":"The diagnostic value and functional roles of phosphoglycerate mutase 1 in glioma.","volume":"36","author":"Xu","year":"2016","journal-title":"Oncol Rep"},{"key":"R4-20260805","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/ijc.28637","article-title":"The role of phosphoglycerate mutase 1 in tumor aerobic glycolysis and its potential therapeutic implications.","volume":"135","author":"Jiang","year":"2014","journal-title":"Int J Cancer"},{"key":"R5-20260805","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/nbt1149","article-title":"Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling.","volume":"23","author":"Evans","year":"2005","journal-title":"Nat Biotechnol"},{"key":"R6-20260805","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3389\/fphar.2017.00325","article-title":"Identification of epigallocatechin-3-gallate as an inhibitor of phosphoglycerate mutase 1.","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"key":"R7-20260805","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/aps.2017.37","article-title":"Conformation and dynamics of the C-terminal region in human phosphoglycerate mutase 1.","volume":"38","author":"Liu","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3892\/or.2013.2933","article-title":"Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway.","volume":"31","author":"Ma","year":"2014","journal-title":"Oncol Rep"},{"key":"R9-20260805","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bmc.2018.02.044","article-title":"Xanthone derivatives as phosphoglycerate mutase 1 inhibitors: design, synthesis, and biological evaluation.","volume":"26","author":"Wang","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"R10-20260805","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.neuron.2024.01.004","article-title":"Advances in structure-based drug design: the potential for precision therapeutics in psychiatric disorders.","volume":"112","author":"Cao","year":"2024","journal-title":"Neuron"},{"key":"R11-20260805","doi-asserted-by":"crossref","first-page":"1492847","DOI":"10.3389\/fmolb.2024.1492847","article-title":"Identification of potential bioactive phytochemicals for the inhibition of platelet-derived growth factor receptor \u03b2: a structure-based approach for cancer therapy.","volume":"11","author":"Habib","year":"2024","journal-title":"Front Mol Biosci"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"18125","DOI":"10.1038\/s41598-021-96917-0","article-title":"Mechanistic insights into the Japanese encephalitis virus RNA dependent RNA polymerase protein inhibition by bioflavonoids from Azadirachta indica.","volume":"11","author":"Dwivedi","year":"2021","journal-title":"Sci Rep"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"R16-20260805","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1021\/ct300203w","article-title":"Improving the prediction of absolute solvation free energies using the next generation OPLS force field.","volume":"8","author":"Shivakumar","year":"2012","journal-title":"J Chem Theory Comput"},{"key":"R18-20260805","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10822-013-9643-9","article-title":"Effects of histidine protonation and rotameric states on virtual screening of M. tuberculosis RmlC.","volume":"27","author":"Kim","year":"2013","journal-title":"J Comput Aided Mol Des"},{"key":"R19-20260805","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.","volume":"47","author":"Friesner","year":"2004","journal-title":"J Med Chem"},{"key":"R21-20260805","doi-asserted-by":"crossref","first-page":"10096","DOI":"10.1063\/1.1808117","article-title":"A modified TIP3P water potential for simulation with Ewald summation.","volume":"121","author":"Price","year":"2004","journal-title":"J Chem Phys"},{"key":"R23-20260805","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1080\/07391102.2021.2015446","article-title":"Computational investigation of potent inhibitors against YsxC: structure-based pharmacophore modeling, molecular docking, molecular dynamics, and binding free energy.","volume":"41","author":"Kumari","year":"2023","journal-title":"J Biomol Struct Dyn"},{"key":"R24-20260805","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1080\/07391102.2017.1404935","article-title":"In-Silico molecular docking and simulation studies on novel chalcone and flavone hybrid derivatives with 1, 2, 3-triazole linkage as vital inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.","volume":"36","author":"Thillainayagam","year":"2018","journal-title":"J Biomol Struct Dyn"},{"key":"R25-20260805","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cmet.2019.09.014","article-title":"A novel allosteric inhibitor of phosphoglycerate mutase 1 suppresses growth and metastasis of non-small-cell lung cancer.","volume":"30","author":"Huang","year":"2019","journal-title":"Cell Metab"},{"key":"R26-20260805","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/acs.jctc.7b00028","article-title":"How molecular size impacts RMSD applications in molecular dynamics simulations.","volume":"13","author":"Sargsyan","year":"2017","journal-title":"J Chem Theory Comput"},{"key":"R27-20260805","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1080\/07391102.2020.1852968","article-title":"Computational guided identification of novel potent inhibitors of N-terminal domain of nucleocapsid protein of severe acute respiratory syndrome coronavirus 2.","volume":"40","author":"Dhankhar","year":"2022","journal-title":"J Biomol Struct Dyn"},{"key":"R28-20260805","doi-asserted-by":"crossref","first-page":"e0119264","DOI":"10.1371\/journal.pone.0119264","article-title":"Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis.","volume":"10","author":"Mart\u00ednez","year":"2015","journal-title":"PLoS One"},{"key":"R29-20260805","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1080\/07391102.2023.2292291","article-title":"Molecular docking and ADMET studies of halogenated metabolites from marine sponges as inhibitors of wild-type and mutants PBP2 in Neisseria gonorrhoeae.","volume":"43","author":"Alanzi","year":"2025","journal-title":"J Biomol Struct Dyn"},{"key":"R30-20260805","doi-asserted-by":"crossref","first-page":"1392650","DOI":"10.3389\/fchem.2024.1392650","article-title":"ROS1 kinase inhibition reimagined: identifying repurposed drug via virtual screening and molecular dynamics simulations for cancer therapeutics.","volume":"12","author":"Alrouji","year":"2024","journal-title":"Front Chem"},{"key":"R31-20260805","doi-asserted-by":"crossref","first-page":"5515692","DOI":"10.1155\/2021\/5515692","article-title":"In silico drug screening analysis against the overexpression of PGAM1 gene in different cancer treatments.","volume":"2021","author":"Fareed","year":"2021","journal-title":"Biomed Res Int"},{"key":"R32-20260805","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jprot.2015.11.027","article-title":"Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer.","volume":"132","author":"Peng","year":"2016","journal-title":"J Proteomics"},{"key":"R33-20260805","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2174\/1574893615666191219094216","article-title":"Relevance of molecular docking studies in drug designing.","volume":"15","author":"Jakhar","year":"2020","journal-title":"Curr Bioinform"},{"key":"R34-20260805","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/pr9010071","article-title":"Molecular dynamics simulations in drug discovery and pharmaceutical development.","volume":"9","author":"Salo-Ahen","year":"2020","journal-title":"Processes"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:01:21Z","timestamp":1785945681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":29,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048660","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"2025-01-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}